HEALTH PROFESSIONAL · SOURCE READING

Poly (ADP-ribose) polymerase (PARP) inhibitor therapy

Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 25, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Metastatic Breast Cancer / Metastatic HER2-Negative Hormone Receptor–Positive Breast Cancer / Sequencing therapy for hormone receptor–positive metastatic breast cancer

Patients with hormone receptor-positive metastatic breast cancer and a germline BRCA variant are eligible for PARP inhibitor therapy. For more information, see the Germline BRCA-Mutated Metastatic Breast Cancer section.

Source links and citations

Germline BRCA-Mutated Metastatic Breast Cancer

Preserved source evidence · Not medical advice